Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma

NCT05505461 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of Esophagogastric Junction

Interventions

DRUG: neoadjuvant Radiation plus SOX and PD-1 antibody

Sponsor

Peking University People's Hospital